title: Effect of alginate-chitosan sustained release microcapsules for transhepatic arterial embolization in VX2 rabbit liver cancer model.
abstract: Two lipid-solid dispersion loading Norcantharidin sustained-released microspheres of alginate-chitosan (NCTD/LSD-ACMs) were prepared via the emulsification-gelation method. The effects of microspheres for transarterial hepatic chemoembolization were evaluated in VX2 rabbit liver cancer model. The VX2 animal model was established by biopsy needle, divided randomly into four groups, and disposed with three preparations including NCTD/LSD-ACMs (60-120 μm), NCTD/LSD-ACMs(120-200 μm), and NCTD solution through the hepatic arteries compared with the untreated group (control group). The serum of all rabbits before and at 3, 7, and 14 days after embolization was collected to determine the level of aspartate aminotransferase (AST). The AST level increased in the three treated groups on the first day compared with the control group (p < 0.05), and was higher in the two embolization groups (with no significant difference, p >0.05) than that in the NCTD group (p < 0.05). The tumor growth rates, which were significantly decreased in the two embolization groups compared with that in the control group, and the degree of liver cell necrosis assessed by the histopathological specimens, were used to evaluate the embolization effect. Liquefactive necrosis and coagulative necrosis were observed in the two embolization groups. The results showed that NCTD/LSD-ACMs are a potential candidate for embolization of liver cancer.
authors.affiliation: Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou, People's Republic of China.
authors.forename: Guang-Yu
authors.initials: GY
authors.lastname: Zhang
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Zhou
authors.forename: Xin-Ying
authors.initials: XY
authors.lastname: Zhou
authors.forename: Qing-Yi
authors.initials: QY
authors.lastname: Wen
authors.forename: Ben-Gang
authors.initials: BG
authors.lastname: You
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Xue-Nong
authors.initials: XN
authors.lastname: Zhang
authors.forename: Yong
authors.initials: Y
authors.lastname: Jin
mesh_terms: D000464:Alginates / Q000494:pharmacology*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D049109:Cell Proliferation / Q000187:drug effects; D048271:Chitosan / Q000494:pharmacology*; D004195:Disease Models, Animal; D004621:Embolization, Therapeutic; D020723:Glucuronic Acid / Q000494:pharmacology; D006499:Hepatic Artery / Q000000981:diagnostic imaging / Q000187:drug effects*; D006603:Hexuronic Acids / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D008113:Liver Neoplasms / Q000097:blood / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D019919:Prosthesis Implantation; D011817:Rabbits; D011859:Radiography
chemical_list: D000464:Alginates; D006603:Hexuronic Acids; D020723:Glucuronic Acid; D048271:Chitosan; D001219:Aspartate Aminotransferases
keywords: VX2 cancer model; alginate; chitosan; embolization; microspheres; norcantharidin